HK1141299A1 - Cross-species-specific bispecific binders - Google Patents

Cross-species-specific bispecific binders

Info

Publication number
HK1141299A1
HK1141299A1 HK10107647.0A HK10107647A HK1141299A1 HK 1141299 A1 HK1141299 A1 HK 1141299A1 HK 10107647 A HK10107647 A HK 10107647A HK 1141299 A1 HK1141299 A1 HK 1141299A1
Authority
HK
Hong Kong
Prior art keywords
species
cross
specific bispecific
bispecific binders
binders
Prior art date
Application number
HK10107647.0A
Other languages
English (en)
Inventor
Matthias Klinger
Tobias Raum
Doris Rau
Susanne Mangold
Roman Kischel
Ralf Lutterbuese
Patrick Hoffmann
Peter Kufer
Original Assignee
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39609399&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1141299(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh
Publication of HK1141299A1 publication Critical patent/HK1141299A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polyesters Or Polycarbonates (AREA)
HK10107647.0A 2007-04-03 2010-08-10 Cross-species-specific bispecific binders HK1141299A1 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP07006990 2007-04-03
EP07006988 2007-04-03
US91366807P 2007-04-24 2007-04-24
EP07020646 2007-10-22
EP07020641 2007-10-22
EP07020640 2007-10-22
EP08004741 2008-03-13
PCT/EP2008/002663 WO2008119566A2 (en) 2007-04-03 2008-04-03 Cross-species-specific bispecific binders

Publications (1)

Publication Number Publication Date
HK1141299A1 true HK1141299A1 (en) 2010-11-05

Family

ID=39609399

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10107647.0A HK1141299A1 (en) 2007-04-03 2010-08-10 Cross-species-specific bispecific binders

Country Status (14)

Country Link
US (4) US20100183615A1 (ko)
EP (1) EP2155788B1 (ko)
JP (1) JP6016747B2 (ko)
KR (1) KR101626988B1 (ko)
CN (1) CN101675077B (ko)
AU (1) AU2008234019B2 (ko)
CA (1) CA2682626A1 (ko)
HK (1) HK1141299A1 (ko)
HR (1) HRP20120759T1 (ko)
IL (1) IL201338A (ko)
MX (1) MX2009010611A (ko)
PL (1) PL2155788T3 (ko)
WO (1) WO2008119566A2 (ko)
ZA (1) ZA200907116B (ko)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10100098B2 (en) * 2006-12-13 2018-10-16 Stelis Biopharma Private Limited Insulin production methods and proinsulin constructs
RS53008B2 (sr) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
WO2010037838A2 (en) * 2008-10-01 2010-04-08 Micromet Ag Cross-species-specific single domain bispecific single chain antibody
HRP20160857T4 (hr) 2008-10-01 2022-12-09 Amgen Research (Munich) Gmbh Bispecifična jednolančana protutijela, specifična za visokomolekulske ciljne antigene
ES2588155T3 (es) * 2008-10-01 2016-10-31 Amgen Research (Munich) Gmbh Anticuerpo biespecífico de cadena sencilla PSMAxCD3 específico entre especies
AU2009299791B2 (en) 2008-10-01 2016-02-25 Amgen Research (Munich) Gmbh Cross-species-specific PSCAxCD3, CD19xCD3, C-METxCD3, EndosialinxCD3, EpCAMxC D3, IGF-1RxCD3 or FAPalpha xCD3 bispecific single chain antibody
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
JP2011026294A (ja) * 2009-06-26 2011-02-10 Canon Inc 化合物
US8993715B2 (en) * 2009-07-06 2015-03-31 Canon Kabushiki Kaisha Labeled protein and method for obtaining the same
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
TWI629357B (zh) * 2009-10-02 2018-07-11 安進研究（慕尼黑）有限責任公司 跨物種特異性的ＰＳＭＡｘＣＤ３雙特異性單鏈抗體
TWI653333B (zh) * 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
US8557961B2 (en) 2010-04-02 2013-10-15 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
EP2377888A1 (en) * 2010-04-07 2011-10-19 Corimmun GmbH Fusion protein
CN103052649B (zh) 2010-07-29 2015-12-16 Xencor公司 具有修改的等电点的抗体
JP6023717B2 (ja) 2010-11-10 2016-11-09 アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｄ３特異的結合ドメインによって引き起こされる有害作用の予防
AU2012245260B2 (en) 2011-04-22 2016-09-08 Aptevo Research And Development Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
JP6400470B2 (ja) 2011-05-16 2018-10-03 ジェネロン（シャンハイ）コーポレイション リミテッド 多重特異性Ｆａｂ融合タンパク質および使用法
JP6141831B2 (ja) 2011-05-21 2017-06-07 マクロジェニクス，インコーポレーテッド ヒト及び非ヒトｃｄ３に結合可能なｃｄ３結合分子
BR112014004168A2 (pt) 2011-08-23 2017-12-12 Roche Glycart Ag anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
WO2013048243A1 (en) * 2011-09-29 2013-04-04 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
UY34504A (es) 2011-12-09 2013-06-28 Amgen Res Munich Gmbh Prevención de los efectos adversos causados por los anticuerpos biespecíficos EpCAMxCD3
JP6169608B2 (ja) * 2011-12-29 2017-07-26 エータイアー ファーマ， インコーポレイテッド アスパルチルｔＲＮＡシンテターゼ−Ｆｃコンジュゲート
JP6154895B2 (ja) 2012-06-07 2017-06-28 デューク ユニバーシティー ヒト二重特異性ＥＧＦＲｖＩＩＩ抗体結合分子
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
CN104704004B (zh) 2012-10-08 2019-12-31 罗切格利卡特公司 包含两个Fab片段的无Fc的抗体及使用方法
CN104780940B (zh) 2012-11-06 2017-11-07 拜耳制药股份公司 用于双特异性t细胞衔接体(bites)的制剂
CN104271602B (zh) * 2012-11-21 2020-08-21 武汉友芝友生物制药有限公司 双特异性抗体
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
SI2943511T1 (sl) 2013-01-14 2020-01-31 Xencor, Inc. Novi heterodimerni proteini
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
EP2762497A1 (en) 2013-02-05 2014-08-06 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP2953972B1 (en) 2013-02-05 2020-07-08 EngMab Sàrl Method for the selection of antibodies against bcma
US9486475B2 (en) 2013-02-08 2016-11-08 Amgen Research (Munich) Gmbh PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
JO3529B1 (ar) 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
BR112015017800A2 (pt) 2013-02-26 2017-11-21 Roche Glycart Ag moléculas de ligação ao antígeno biespecífica ativadora de célula t, polinucleotídeo, polipeptídeo, vetor, célula hospedeira, método de produção da molécula de ligação ao antígeno biespecífica ativadora de célula t, composição farmacêutica e uso da molécula de ligação ao antígeno biespecífica ativadora de célula t
PL2961771T3 (pl) 2013-02-26 2020-06-01 Roche Glycart Ag Dwuswoiste cząsteczki wiążące antygen swoisty dla CD3 i CEA aktywujące limfocyty T
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
DK2970486T3 (en) 2013-03-15 2018-08-06 Xencor Inc MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US20140302037A1 (en) 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
MX357011B (es) 2013-03-15 2018-06-22 Amgen Inc Anticuerpos biespecificos heterodimericos.
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
KR102531517B1 (ko) * 2013-07-05 2023-05-12 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
ES2912932T3 (es) 2013-07-25 2022-05-30 Cytomx Therapeutics Inc Anticuerpos multiespecíficos, anticuerpos activables multiespecíficos y procedimientos de uso de los mismos
WO2015048272A1 (en) 2013-09-25 2015-04-02 Amgen Inc. V-c-fc-v-c antibody
EP3083689B1 (en) * 2013-12-17 2020-05-27 Genentech, Inc. Anti-cd3 antibodies and methods of use
AU2015204840B2 (en) * 2014-01-07 2020-01-30 Bioatla, Llc Proteins targeting orthologs
EP3470435B1 (en) 2014-02-28 2020-08-05 Merus N.V. Antibody that binds erbb-2 and erbb-3
US10844127B2 (en) 2014-02-28 2020-11-24 Merus N.V. Antibodies that bind EGFR and ErbB3
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
SG10202008629XA (en) 2014-03-28 2020-10-29 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
LT3531133T (lt) 2014-05-30 2023-11-10 Amgen Research (Munich) Gmbh Ūminės b pirmtakų limfoblastinės leukemijos pacientų rizikos stratifikacija
BR112017001579A2 (pt) 2014-07-25 2017-11-21 Cytomx Therapeutics Inc anticorpos anti-cd3, anticorpos anti-cd3 ativáveis, anticorpos anti-cd3 multiespecíficos, anticorpos anti-cd3 ativáveis multiespecíficos e métodos de uso dos mesmos
MA50584A (fr) 2014-08-04 2020-09-16 Hoffmann La Roche Molécules bispécifiques de liaison à l'antigène activant des lymphocytes t
AR101846A1 (es) 2014-09-12 2017-01-18 Genentech Inc Anticuerpos anti-cll-1 e inmunoconjugados
AU2015323313B2 (en) 2014-09-25 2021-04-01 Amgen Inc. Protease-activatable bispecific proteins
KR102614189B1 (ko) 2014-11-17 2023-12-18 리제너론 파아마슈티컬스, 인크. Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법
PL3221355T3 (pl) 2014-11-20 2021-03-08 F. Hoffmann-La Roche Ag Terapia skojarzona składająca się z dwuswoistych aktywujących limfocyty T cząsteczek wiążących antygen CD3 i receptor folianowy 1 (FolR1) oraz antagonistów wiązania osi PD-1
SG11201703800PA (en) * 2014-11-24 2017-06-29 Regeneron Pharma Non-human animals expressing humanized cd3 complex
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
NZ732144A (en) 2014-11-26 2020-04-24 Xencor Inc Heterodimeric antibodies that bind cd3 and tumor antigens
AU2015353416C1 (en) 2014-11-26 2022-01-27 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CD38
EP3029067A1 (en) 2014-12-01 2016-06-08 Deutsches Krebsforschungszentrum Use of blocking-reagents for reducing unspecific T cell-activation
LT3227336T (lt) 2014-12-05 2019-09-25 F. Hoffmann-La Roche Ag Anti-cd79b antikūnai ir jų naudojimo būdai
EP3237449A2 (en) 2014-12-22 2017-11-01 Xencor, Inc. Trispecific antibodies
KR20210096326A (ko) 2015-02-24 2021-08-04 바이오아트라, 인코퍼레이티드 조건부 활성 생체 단백질
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
CN104829729B (zh) * 2015-04-03 2018-08-14 复旦大学 一种携带抗Her2/CD3双特异性功能蛋白的人T细胞制备
CN107709363A (zh) * 2015-05-01 2018-02-16 基因泰克公司 掩蔽抗cd3抗体和使用方法
JP2018516248A (ja) 2015-05-29 2018-06-21 アンフィヴェナ セラピューティクス，インク． 二重特異性のｃｄ３３およびｃｄ３結合タンパク質を使用する方法
WO2016204966A1 (en) 2015-06-16 2016-12-22 Genentech, Inc. Anti-cd3 antibodies and methods of use
SI3310814T1 (sl) 2015-06-16 2023-11-30 F. Hoffmann - La Roche Ag HUMANIZIRANA IN AFINITETNO DOZORELA PROTITELESA PROTI FcRH5 IN METODE ZA NJIHOVO UPORABO
JP6996983B2 (ja) 2015-06-16 2022-02-21 ジェネンテック， インコーポレイテッド 抗ｃｌｌ－１抗体及び使用方法
CN107709356A (zh) 2015-06-26 2018-02-16 南加利福尼亚大学 用于肿瘤特异性活化的掩蔽嵌合抗原受体t细胞
TWI829617B (zh) * 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
WO2017021450A1 (en) 2015-08-03 2017-02-09 Engmab Ag Monoclonal antibodies against bcma
LT3337824T (lt) 2015-08-17 2020-09-25 Janssen Pharmaceutica Nv Anti-bcma antikūnai, bispecifinės antigeną surišančios molekulės, kurios suriša bcma ir cd3, ir jų panaudojimas
TWI744247B (zh) 2015-08-28 2021-11-01 美商亞穆尼克斯製藥公司 嵌合多肽組合體以及其製備及使用方法
KR20180053322A (ko) 2015-09-21 2018-05-21 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
CA2990755A1 (en) 2015-10-02 2017-04-06 F. Hoffman-La Roche Ag Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
KR20180100305A (ko) 2015-10-23 2018-09-10 메뤼스 엔.페. 암 성장을 억제하는 결합 분자
CR20180250A (es) 2015-11-02 2018-10-01 Janssen Pharmaceutica Nv Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y uso de estas
CN108699136B (zh) 2015-12-07 2022-03-18 Xencor股份有限公司 结合cd3和psma的异二聚抗体
IL257696B1 (en) 2015-12-09 2024-07-01 Hoffmann La Roche Antibody against CD20 type II to reduce the formation of antibodies against drugs
TW202208440A (zh) 2015-12-14 2022-03-01 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
US10596257B2 (en) 2016-01-08 2020-03-24 Hoffmann-La Roche Inc. Methods of treating CEA-positive cancers using PD-1 axis binding antagonists and anti-CEA/anti-CD3 bispecific antibodies
EP3192810A1 (en) 2016-01-14 2017-07-19 Deutsches Krebsforschungszentrum Psma binding antibody and uses thereof
UY37127A (es) 2016-02-17 2017-08-31 Macrogenics Inc Moléculas de unión a ror1, y métodos de uso de las mismas
CA3017776A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
RS64266B1 (sr) 2016-03-22 2023-07-31 Hoffmann La Roche Bispecifični molekul koji aktivira t ćeliju koji se aktivira proteazom
KR102514317B1 (ko) 2016-04-15 2023-03-27 마크로제닉스, 인크. 신규 b7-h3-결합 분자, 그것의 항체 약물 콘쥬게이트 및 그것의 사용 방법
EP3463464A4 (en) 2016-06-07 2020-07-01 MacroGenics, Inc. COMBINATION THERAPY
KR20230054508A (ko) 2016-06-14 2023-04-24 젠코어 인코포레이티드 이중특이적 체크포인트 억제제 항체
CA3029209A1 (en) 2016-06-21 2017-12-28 Teneobio, Inc. Cd3 binding antibodies
CN116063545A (zh) 2016-06-28 2023-05-05 Xencor股份有限公司 结合生长抑素受体2的异源二聚抗体
TWI781108B (zh) 2016-07-20 2022-10-21 比利時商健生藥品公司 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN109843325B (zh) 2016-09-14 2023-10-03 特尼奥生物股份有限公司 Cd3结合抗体
CN109843926B (zh) 2016-09-30 2023-01-20 豪夫迈·罗氏有限公司 针对cd3的双特异性抗体
JP7273453B2 (ja) 2016-10-14 2023-05-15 ゼンコア インコーポレイテッド ＩＬ－１５／ＩＬ－１５ＲアルファＦｃ融合タンパク質およびＰＤ－１抗体の断片を含む二重特異性ヘテロ二量体融合タンパク質
CA3041183A1 (en) 2016-11-02 2018-05-11 Engmab Sarl Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
WO2018093821A1 (en) 2016-11-15 2018-05-24 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
KR20230052309A (ko) 2016-12-21 2023-04-19 테네오바이오, 인코포레이티드 항-bcma 중쇄-단독 항체
IL267589B1 (en) 2016-12-23 2024-07-01 Macrogenics Inc ADAM9 binding molecules and methods of their use
SG11201908971RA (en) 2017-03-31 2019-10-30 Merus Nv Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
EP3615571A1 (en) * 2017-04-24 2020-03-04 Ichnos Sciences SA T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
WO2018237037A2 (en) 2017-06-20 2018-12-27 Teneobio, Inc. HEAVY CHAIN ANTIBODY ONLY ANTI-BCMA
JP2020529832A (ja) 2017-06-30 2020-10-15 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５Ｒαおよび抗原結合ドメインを含む標的化ヘテロダイマーＦｃ融合タンパク質
CN111094351B (zh) 2017-08-09 2024-07-12 美勒斯公司 结合EGFR和cMET的抗体
EP3664814A4 (en) 2017-08-11 2021-05-05 City of Hope RNA APTAMERS AGAINST TRANSFERRIN RECEPTOR (TFR)
US11472880B2 (en) 2017-08-14 2022-10-18 Morphosys Ag Humanized antibodies for CD3
BR112020004992A2 (pt) * 2017-09-21 2020-10-06 WuXi Biologics Ireland Limited anticorpos, composição farmacêutica, polinucleotídeo, vetor, célula hospedeira, métodos de expressar o anticorpo e de modulação, métodos para tratar uma doença, para ativar células t, para promover o processamento, para detectar e para diagnosticar, uso do anticorpo e kit
EP3694885A1 (en) 2017-10-14 2020-08-19 CytomX Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
KR20200085828A (ko) 2017-11-08 2020-07-15 젠코어 인코포레이티드 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11319355B2 (en) 2017-12-19 2022-05-03 Xencor, Inc. Engineered IL-2 Fc fusion proteins
CA3085950A1 (en) 2017-12-21 2019-06-27 Amunix Pharmaceuticals, Inc. Release segments and binding compositions comprising same
AR115360A1 (es) 2018-02-08 2021-01-13 Genentech Inc Moléculas de unión al antígeno y métodos de uso
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
JP2021520829A (ja) 2018-04-18 2021-08-26 ゼンコア インコーポレイテッド ＩＬ−１５／ＩＬ−１５ＲＡ Ｆｃ融合タンパク質およびＴＩＭ−３抗原結合ドメインを含む、ＴＩＭ−３標的化ヘテロ二量体融合タンパク質
EP3781599A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
US12012461B2 (en) 2018-05-16 2024-06-18 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
JOP20190116A1 (ar) 2018-05-24 2019-11-24 Janssen Biotech Inc الأجسام المضادة لتكتل التمايز 33 (cd33)، والأجسام المضادة ثنائية النوعية لتكتل التمايز 33 (cd33)/تكتل التمايز 3 (cd3) واستخداماتها
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
EP3802599B1 (en) 2018-06-03 2023-12-20 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
WO2020047389A1 (en) 2018-08-31 2020-03-05 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
EP3623383A1 (en) 2018-09-11 2020-03-18 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Improved bispecific flt3xcd3 antigen binding proteins
BR112021004686A2 (pt) 2018-09-11 2021-06-08 Eberhard Karls Universität Tübingen proteínas de ligação de antígeno anti-flt3 melhoradas
US11358999B2 (en) 2018-10-03 2022-06-14 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
CN109402168A (zh) * 2018-10-30 2019-03-01 深圳新诺微环生物科技有限公司 微环dna表达连接her2阳性细胞与效应细胞的桥接分子及其应用
JP7410143B2 (ja) 2018-11-01 2024-01-09 山▲東▼新▲時▼代▲薬▼▲業▼有限公司 二重特異性抗体及びその用途
AU2019392711A1 (en) 2018-12-05 2021-05-20 Morphosys Ag Multispecific antigen-binding molecules
WO2020180726A1 (en) 2019-03-01 2020-09-10 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
MA56120A (fr) 2019-06-07 2022-04-13 Amgen Inc Constructions de liaison bispécifiques
UY38748A (es) 2019-06-14 2021-01-29 Teneobio Inc Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
AU2020350205A1 (en) 2019-09-18 2022-05-12 Lamkap Bio Alpha AG Bispecific antibodies against CEACAM5 and CD3
EP3822288A1 (en) 2019-11-18 2021-05-19 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
US20230067182A1 (en) * 2019-11-29 2023-03-02 Boe Technology Group Co., Ltd. Data Processing Device and Method, and Computer Readable Storage Medium
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
PE20221511A1 (es) 2019-12-13 2022-10-04 Genentech Inc Anticuerpos anti-ly6g6d y metodos de uso
BR112022013725A2 (pt) 2020-01-13 2022-10-11 Aptevo Res & Development Llc Formulações para agentes terapêuticos proteicos
AU2021207632A1 (en) 2020-01-13 2022-07-07 Aptevo Research And Development Llc Methods and compositions for preventing adsorption of therapeutic proteins to drug delivery system components
MX2022009049A (es) * 2020-01-23 2022-11-08 Exuma Biotech Corp Receptores de antígenos quiméricos para her2 y métodos de uso de estos.
US20230203161A1 (en) 2020-04-29 2023-06-29 Teneobio, Inc Multispecific heavy chain antibodies with modified heavy chain constant regions
BR112022022800A2 (pt) 2020-05-11 2022-12-13 Janssen Biotech Inc Métodos para tratamento de mieloma múltiplo
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
EP4161969A1 (en) 2020-06-04 2023-04-12 Amgen Inc. Bispecific binding constructs
US11780920B2 (en) 2020-06-19 2023-10-10 Hoffmann-La Roche Inc. Antibodies binding to CD3 and CD19
KR20230166150A (ko) 2020-08-19 2023-12-06 젠코어 인코포레이티드 항-cd28 조성물
EP4255931A1 (en) 2020-12-03 2023-10-11 Amgen Inc. Immunoglobuline constructs with multiple binding domains
CR20230398A (es) 2021-02-16 2023-11-15 Janssen Pharmaceutica Nv Anticuerpo triespecífico dirigido a bcma, gprc5d, y cd3
KR20230156079A (ko) 2021-03-09 2023-11-13 젠코어 인코포레이티드 Cd3과 cldn6에 결합하는 이종이량체 항체
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
BR112023019484A2 (pt) 2021-03-24 2023-12-05 Janssen Biotech Inc Anticorpo triespecífico que tem como alvo cd79b, cd20 e cd3
KR20240024819A (ko) 2021-05-21 2024-02-26 압테보 리서치 앤드 디벨롭먼트 엘엘씨 단백질 치료제의 투약 요법
WO2023288267A1 (en) 2021-07-14 2023-01-19 2Seventy Bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
EP4412652A1 (en) * 2021-10-06 2024-08-14 The Wistar Institute of Anatomy and Biology Novel immune cell engagers for immunotherapy
WO2023196997A2 (en) 2022-04-08 2023-10-12 2Seventy Bio, Inc. Multipartite receptor and signaling complexes
TW202406571A (zh) 2022-04-13 2024-02-16 美商建南德克公司 莫蘇妥珠單抗之醫藥組成物及其使用方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2206447T3 (es) * 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
IT1271461B (it) * 1993-12-01 1997-05-28 Menarini Ricerche Sud Spa Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6037453A (en) * 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
WO1997000271A1 (en) * 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
US20020173629A1 (en) * 1997-05-05 2002-11-21 Aya Jakobovits Human monoclonal antibodies to epidermal growth factor receptor
US5994511A (en) * 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
DE69909459T2 (de) * 1998-04-21 2004-05-27 Micromet Ag Cd19xcd3 spezifische polypeptide und deren verwendung
KR20010071271A (ko) * 1998-05-15 2001-07-28 존 비. 랜디스 방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법
JP4298498B2 (ja) * 2001-06-13 2009-07-22 ゲンマブ エー／エス 上皮成長因子受容体（ｅｇｆｒ）に対するヒトモノクローナル抗体
EP2289942B1 (en) * 2002-04-10 2013-07-31 Genentech, Inc. Anti-HER2 antibody variants
WO2003089930A1 (en) * 2002-04-22 2003-10-30 Georgetown University Peripheral-type benzodiazepine receptor expression level as an index of organ damage and regeneration
JP3803790B2 (ja) * 2003-02-17 2006-08-02 株式会社東北テクノアーチ 新規なダイアボディ型二重特異性抗体
SI1673398T1 (sl) * 2003-10-16 2011-05-31 Micromet Ag Multispecifiäśne deimunizirajoäśe cd3 povezovalne molekule
US20050142133A1 (en) * 2003-12-03 2005-06-30 Xencor, Inc. Optimized proteins that target the epidermal growth factor receptor
US7235641B2 (en) * 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
WO2005077982A1 (en) * 2004-02-16 2005-08-25 Micromet Ag Less immunogenic binding molecules
US20050266008A1 (en) * 2004-03-29 2005-12-01 Medarex, Inc. Human anti-IRTA-5 antibodies
SG10201606980VA (en) 2004-06-03 2016-10-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
AU2005285347A1 (en) * 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
UA92505C2 (ru) 2005-09-12 2010-11-10 Новиммюн С.А. Композиции на основе антитела против cd3
DK1940881T3 (en) * 2005-10-11 2017-02-20 Amgen Res (Munich) Gmbh COMPOSITIONS WITH ARTICLE CROSS-SPECIFIC ANTIBODIES AND APPLICATIONS THEREOF
EP1945674A2 (en) * 2005-11-03 2008-07-23 Genentech, Inc. Therapeutic anti-her2 antibody fusion polypeptides
JP5618549B2 (ja) * 2007-03-15 2014-11-05 ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド Ｅｇｆｒ抗体及びｓｒｃ阻害剤を用いる治療方法及び関連製剤
RS53008B2 (sr) * 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
JP2010524435A (ja) * 2007-04-03 2010-07-22 マイクロメット アーゲー 種間特異的二重特異性バインダー

Also Published As

Publication number Publication date
CN101675077B (zh) 2013-09-04
IL201338A (en) 2015-05-31
US20120244162A1 (en) 2012-09-27
KR20100016199A (ko) 2010-02-12
PL2155788T3 (pl) 2013-02-28
US20100183615A1 (en) 2010-07-22
MX2009010611A (es) 2010-03-26
WO2008119566A3 (en) 2009-01-08
AU2008234019A1 (en) 2008-10-09
US20160152707A1 (en) 2016-06-02
KR101626988B1 (ko) 2016-06-02
WO2008119566A2 (en) 2008-10-09
EP2155788A2 (en) 2010-02-24
HRP20120759T1 (hr) 2012-10-31
AU2008234019B2 (en) 2014-05-29
JP2014064568A (ja) 2014-04-17
CN101675077A (zh) 2010-03-17
JP6016747B2 (ja) 2016-10-26
ZA200907116B (en) 2011-03-30
CA2682626A1 (en) 2008-10-09
EP2155788B1 (en) 2012-06-27
IL201338A0 (en) 2010-05-31
US20200095319A1 (en) 2020-03-26

Similar Documents

Publication Publication Date Title
HK1141299A1 (en) Cross-species-specific bispecific binders
GB2451719C (en) Binders
SI2155788T1 (sl) Bispecifični vezavni element specifičen za križane vrste
EP2137223A4 (en) COMPOSITE MAILLARD-RESOLE BINDERS
IL234081B (en) Antibody binds cd3–epsilon in different species
DK200800103A (en) Integreret føringskant for vindturbineblad
IL202616A0 (en) Substituted imidazoheterocycles
IL201340A (en) Antidote 3dc - epsilon in various species
ZA201001683B (en) Substituted piperidino-dihydrothienopyrimidines
GB0724258D0 (en) Novel combinations
EP2108522A4 (en) BINDER
GB0701574D0 (en) Wave-dissipating block
IL200965A0 (en) Substituted tetrahydropyrroloquinolines
GB0703800D0 (en) Fascines
GB0701606D0 (en) Adjustachair
GB0712532D0 (en) Binders
GB0812743D0 (en) Binders
GB0721236D0 (en) File clipz
HK1102527A2 (en) Multi purpose case
GB0724281D0 (en) Combinations
GB0725328D0 (en) Data-handleing means
GB0603219D0 (en) Binders
GB0724415D0 (en) CV-kinisis II
ZA201000435B (en) Substituted imidazoheterocycles
HU3408U (en) Block

Legal Events

Date Code Title Description
REV Revocation after opposition